Skip to Main content Skip to Navigation
Journal articles

Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells

Sandrine Valsesia-Wittmann 1 Beatrice Clemenceau 2 Anne-Catherine Jallas 1 Jean-yves Blay 1 Aurelien Marabelle 1 Christophe Caux 1 Henri Vie 2 
1 P3I - Innovation en Immonomonitoring et Immunothérapie
2 CRCNA - Centre de Recherche en Cancérologie Nantes-Angers
Document type :
Journal articles
Complete list of metadata
https://www.hal.inserm.fr/inserm-00881032
Contributor : Ed. BMC Connect in order to contact the contributor
Submitted on : Thursday, November 7, 2013 - 1:04:54 PM
Last modification on : Wednesday, November 10, 2021 - 3:32:02 PM
Long-term archiving on: : Saturday, February 8, 2014 - 7:05:09 AM

Files

Vignette du document
2051-1426-1-S1-P176.pdf
Publisher files allowed on an open archive

Identifiers

  • HAL Id : inserm-00881032, version 1

Collections

INSERM | CNRS | UNAM | CRCNA

Citation

Sandrine Valsesia-Wittmann, Beatrice Clemenceau, Anne-Catherine Jallas, Jean-yves Blay, Aurelien Marabelle, et al.. Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells. Journal for Immunotherapy of Cancer, BMJ Publishing Group 2013, 1 (Suppl 1), pp.P176. ⟨inserm-00881032⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

167

Files downloads

183